Adams Q3
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics will institute a 4% price increase for its Mucinex franchise effective July 1, the firm announces during a third-quarter earnings call May 11. Strong market penetration by the brand drove sales for the quarter up 29% to $76 mil., with the entire brand contributing $74.8 mil., the company reports. Net sales of single-ingredient Mucinex (600 mg guaifenesin) grew 20% to $51.9 mil. and sales of Mucinex DM (600 mg guaifenesin/30 mg dextromethorphan) rose 28% to $18.3 mil. Mucinex D (600 mg guaifenesin/60 mg pseudoephedrine), which launched in late October 2005, recorded net sales of $4.7 mil. Adams will allot $50 mil. in ad spend to support a new line of Mucinex pediatric products that are expected to launch in 2006. Separately, the firm will add 25 new representatives to its existing 100-person field force; the new employees are expected to be hired, trained and deployed by July 15...